Are you Dr. Bernstein?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 71 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
601 Elmwood Ave
Box Med
Rochester, NY 14642Phone+1 585-275-0784Fax+1 585-273-5761
Summary
- Dr. Steven Bernstein, MD is a hematologist in Rochester, New York. He is currently licensed to practice medicine in New York. He is affiliated with Highland Hospital and is a Professor at University of Rochester School of Medicine & Dentistry.
Education & Training
- Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1991
- University of ChicagoResidency, Internal Medicine, 1984 - 1987
- New York University School of MedicineClass of 1984
Certifications & Licensure
- NY State Medical License 1985 - 2014
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- 124 citationsRituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” ...Shannon P. Hilchey, Ollivier Hyrien, Tim R. Mosmann, Alexandra M. Livingstone, Jonathan W. Friedberg
Blood. 2009-04-16 - 846 citationsCharacterization of a rare IL-10–competent B-cell subset in humans that parallels mouse regulatory B10 cellsYohei Iwata, Takashi Matsushita, Mayuka Horikawa, David J. DiLillo, Koichi Yanaba
Blood. 2011-01-13 - 174 citationsPhase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin LymphomasJonathan W. Friedberg, Daruka Mahadevan, Erin Cebula, Daniel O. Persky, Izidore Lossos
Journal of Clinical Oncology. 2014-01-01
Authored Content
- The Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) Program: Innovative, High-Throughput Clinical Screening of ImmunotherapiesOctober 2018